Free Testosterone & Dehydroepiandrosterone Sulfate Serum Levels in Polycystic Ovary Syndrome Women

Document Type : Original Articles

Authors

Department of Obstetrics and Gynaecology, Ain-Shams University, Cairo, Egypt

Abstract

Objectives: This study designed to detect the prevalence of ovarian and/or adrenal hyperandrogenism in women with Polycystic Ovary Syndrome (PCOS).Materials: One hundred PCOS women included in this cross sectional study after informed consent and approval of the study by local institute ethical committee. Diagnosis of PCOS based on the Rotterdam ESHRE criteria. Studied women underwent complete physical examination with calculation of body mass index (BMI) and assessment of hirsutism by modified Ferriman Gallway score. Clotted blood sample taken from studied women for measurement of serum total testosterone, sex hormone binding globulin (SHBG) and dehydroepiandrosterone sulfate (DHEAS) to detect the prevalence of ovarian and/or adrenal hyperandrogenism in PCOS women. Results: 66% of studied PCOS women presented with hirsutism, 22% of studied PCOS women presented with menstrual irregularities (hypomenorrhea, oligomenorrhea) and dysmenorrhea was the presenting symptom in 12%. Free testosterone was elevated in 50 cases of studied women; DHEAS was elevated in 30 cases of studied women while the remaining 20 cases had elevated both free testosterone and DHEAS. Mean free testosterone was 2.6±1.8 pg/ml and mean DHEAS was 5.5±3.8 mg/l. Conclusion: The ovary is the main source of excess androgen in PCOS (50% of studied women) and excess adrenal androgen found in 30% of studied PCOS women, further large studies recommended to confirm this finding.

Keywords

References

  1. Rosenfield RL. Hirsutism. New England Journal of Medicine. 2005; 353(24):2578–88. doi: 10.1056/nejmcp033496
  2. Hunter MH, Carek PJ. Evaluation and treatment of women with hirsutism. American Family Physician. 2003; 67(12):2565-72. PMID: 12825846
  3. Kirk LF, Hash RB, Katner HP, Jones T. Cushing's disease: clinical manifestations and diagnostic evaluation. American family physician. 2000; 62(5):1119-27.
  4. Georgopoulos NA, Kandaraki E, Panidis D. Hyperandrogenism in PCOS. Diagnosis and Management of Polycystic Ovary Syndrome. 2009; 105–10. doi: 10.1007/978-0-387-09718-3_8
  5. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecological Endocrinology. 1987; 1(3):235–45. doi: 10.3109/09513598709023610
  6. Chang WY, Azziz R. Pathogenesis of hyperandrogenism in polycystic ovary syndrome. Polycystic Ovary Syndrome. 281–94. doi: 10.1007/978-1-59745-108-6_17
  7. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: The complete task force report. Fertility and Sterility. 2009; 91(2):456–88. doi: 10.1016/j.fertnstert.2008.06.035
  8. Gil Junior AB, Rezende APR, Carmo AV do, Duarte EI, Medeiros. [Adrenal androgen participation in the polycystic ovary syndrome (Portuguese)]. Revista Brasileira de Ginecologia e Obstetricia. 2010; 32(11):541–8. doi: 10.1590/s0100-72032010001100005
  9. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction. 2004; 19(1):41–7. doi: 10.1093/humrep/deh098
  10. Abdelazim IA, Elsawah WF. Metabolic syndrome among infertile women with polycystic ovary syndrome. Asian Pacific Journal of Reproduction. 2015; 4(1):44–8. doi: 10.1016/s2305-0500(14)60057-9
  11. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Reviews in Endocrine and Metabolic Disorders. 2007; 8(2):127–41. doi: 10.1007/s11154-007-9046-0
  12. Ibañez L, Jimenez R, de Zegher F. Early puberty-menarche after precocious pubarche: Relation to prenatal growth. Pediatrics. 2006; 117(1):117–21. doi: 10.1542/peds.2005-0664
  13. Diamanti-Kandarakis E. Genetics of polycystic ovary syndrome: Searching for the way out of the labyrinth. Human Reproduction Update. 2005; 11(6):631–43. doi: 10.1093/humupd/dmi025
  14. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertility and Sterility. 1985; 43(2):200–5. doi: 10.1016/s0015-0282(16)48373-1
  15. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology & Metabolism. 2004; 89(6):2745–9. doi: 10.1210/jc.2003-032046
  16. Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethasone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: A prospective placebo-controlled study. Obstetrical & Gynecological Survey. 2006; 61(11):718–20. doi: 10.1097/01.ogx.0000243897.75261.73
Journal of Advanced Medical Sciences and Applied Technologies
Volume 3, Issue 1 - Serial Number 1
11
March 2017
Pages 17-20

Files

Share

How to cite

Statistics